Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
BHVN - Biohaven Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$16.50
DETAILS
HIGH:
$23.00
LOW:
$10.00
MEDIAN:
$16.50
CONSENSUS:
$16.50
UPSIDE:
74.60%
Stock News
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved safety versus GLP-1s; phase 2 POC data is expected in 2H 2026.
Why Biohaven Stock Crushed it on Monday
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 693,452 shares of the company's stock, valued at approximately $7,829,000. Aberdeen Group plc owned 0.66% of Biohaven as
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,518 shares of the company's stock after buying an additional 78,585 shares during the
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and three have given a
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quarter-end value of the position rose by $7.25 million, reflecting both the share increase and stock price changes during the period.
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.
What's Going On With Biohaven Stock On Monday?
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity: Inflammation and Immunology: Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of IgG, with maximum reductions of up to an 87% decrease from baseline within weeks of dosing in a study conducted in healthy volunteers.
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?
The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Goldman Sachs Just Upgraded These 3 Stocks to a Buy Rating
Goldman initiated a buy rating on Biohaven targeting its IgAN treatment in an over $40B U.S. market.
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed investor presentations and updates on its drug pipeline.
Price Targets
Biohaven price target lowered to $18 from $21 at Morgan Stanley
$18.00
(was $8.93)
Terence Flynn
·
Morgan Stanley
Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright
$10.00
(was $10.39)
Douglas Tsao
·
H.C. Wainwright
Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates
$15.00
(was $10.67)
Marc Goodman
·
Leerink Partners
Biohaven initiated with a Buy at Goldman Sachs
$23.00
(was $10.76)
Goldman Sachs
Biohaven upgraded to Outperform from Sector Perform at RBC Capital
$22.00
(was $12.68)
RBC Capital
Biohaven downgraded to Neutral from Buy at H.C. Wainwright
$11.00
(was $8.83)
H.C. Wainwright
Biohaven downgraded to Neutral from Buy at UBS
$11.00
(was $9.24)
UBS
Biohaven price target lowered to $26 from $54 at Morgan Stanley
$26.00
(was $9.45)
Morgan Stanley
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird
$42.00
(was $13.95)
Brian Skorney
·
Robert W. Baird
Immunovant data positive for Biohaven, says Deutsche Bank
$60.00
(was $28.18)
Deutsche Bank
Biohaven price target lowered to $57 from $73 at Bernstein
$57.00
(was $31.37)
Bernstein
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $61 at RBC Capital
$61.00
(was $46.58)
Leonid Timashev
·
RBC Capital
BofA Securities Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
$65.00
(was $52.77)
Jason Gerberry
·
Bank of America Securities
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Leerink Partners
$60.00
(was $44.22)
Marc Goodman
·
Leerink Partners
H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
$59.00
(was $45.94)
Douglas Tsao
·
H.C. Wainwright
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $62 at BofA Securities
$62.00
(was $45.94)
Jason Gerberry
·
Bank of America Securities
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at RBC Capital
$68.00
(was $45.94)
Leonid Timashev
·
RBC Capital
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Baird
$60.00
(was $46.56)
Brian Skorney
·
Robert W. Baird
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN), PT $59
$59.00
(was $46.56)
Thomas Shrader
·
BTIG
Biohaven initiated with a Buy at Jefferies
$57.00
(was $38.08)
Amy Li
·
Jefferies